$GMAB News

Petosemtamab Trial Results May Change The Case For Genmab Stock

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Incyte & Genmab Collaborate to Develop a New Colorectal Cancer Therapy

Genmab Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival with Petosemtamab Plus Pembrolizumab in First-Line Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Genmab shares jump 13% on colorectal cancer drug trial results

Genmab Presents Updated Phase 2 Data For Petosemtamab Plus Pembrolizumab In First-Line PD-L1–Positive Recurrent/Metastatic Head And Neck Cancer, At ESMO Congress 2026

Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply

Genmab Announces Updated Follow-Up Analyses from Phase 2 Study of Petosemtamab Demonstrate Meaningful Objective Response Rates in Patients with Metastatic Colorectal Cancer

Does Genmab Trial Deal Change The Bull Case For Incyte (INCY)?

Incyte (INCY) Starts KRAS G12D Colorectal Cancer Trial Collaboration

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

Genmab stock surges 9% following positive phase 3 ovarian cancer trial results

Genmab Announces Rinatabart Sesutecan (Rina-S®) Demonstrates Statistically Significant Improvement in Progression-Free Survival and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Genmab’s Phase 3 RAINFOL-02 Trial Meets Primary PFS And Key Secondary OS Endpoints, Demonstrating A Statistically Significant And Clinically Meaningful Improvement For Rina-S In Platinum-Resistant Ovarian Cancer

GENMAB A/S -SP ADR (NASDAQ:GMAB) Eyes Breakout as Technical Strength Builds

Genmab Reports Q3 DARZALEX Net Sales Of $4.239B

Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members

Truist Securities Maintains Buy on Genmab, Raises Price Target to $45

Guggenheim Maintains Buy on Genmab, Raises Price Target to $58